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Abstract
Background and Objective Allergy immunotherapy
(AIT) with the SQ grass sublingual immunotherapy
(SLIT)-tablet has been shown to be efficacious, well-tol-
erated and to improve disease-specific health-related
quality of life (HRQoL) in controlled clinical trials. The
aim of our study was to investigate HRQoL in patients with
allergic rhinoconjunctivitis routinely treated with the SLIT-
tablet and taking symptomatic medication as needed
compared with patients treated only with symptomatic
medication.
Methods In a non-interventional, open-label study,
patients treated with the SLIT-tablet were observed for
about 12 months compared with patients only symp-
tomatically treated. Patients assessed their HRQoL with
the 12-Item Short Form Health Survey (SF-12) and the
Rhinitis Quality of Life Questionnaire (RQLQ) in the
grass pollen seasons (GPS) at baseline (GPS1, HRQoL1),
after GPS1 (HRQoL2) and in the following GPS (GPS2,
HRQoL3). Tolerability, compliance, symptoms and med-
ication use were assessed in the SLIT-tablet group by the
physician.
Results Overall, data were analysed in 576 patients.
Mean differences (±SD) in overall scores for HRQoL3
versus HRQoL1 (186 patients) of SF-12 were
?11.4 ± 16.8 (SLIT-tablet) and -3.4 ± 15.7 (symp-
tomatic medication), (p\ 0.0001), and of RQLQ
-1.31 ± 1.07 and ?0.10 ± 0.74 (p\ 0.001), and for
HRQoL3 versus HRQoL2 (238 patients) of SF-12
-1.6 ± 15.3 and -10.0 ± 14.1 (p = 0.0003), and of
RQLQ ?0.22 ± 1.29 and ?1.24 ± 1.30 (p\ 0.0001).
Tolerability and adherence for the SLIT-tablet were com-
parable with data of other non-interventional studies.
Conclusions Routine treatment with the SQ grass SLIT-
tablet resulted in clear improvements in disease-specific
and general quality of life, while no improvements were
observed in patients treated only symptomatically.
Key Points
General (SF-12) and disease-specific (RQLQ)
health-related quality of life scales were observed
not to improve during the grass pollen season in
patients with allergic rhinoconjunctivitis treated only
with symptomatic medication in a real-life setting.
Clear improvements in health-related quality of life
scales were observed in patients treated with the
SQ grass sublingual allergy immunotherapy tablet
and symptomatic medication as needed compared
with the grass pollen season before start of treatment.
Data of this article were published in abstract form in Horn et al. [23]
and Wolf et al. [24].
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1 Introduction
Allergic rhinoconjunctivitis is associated with impairments
in the way patients function in day-to-day life and may
significantly limit the health-related quality of life
(HRQoL) of the patient as well as affecting school learn-
ing, performance and work productivity [1].
HRQoL includes a large set of physical and psycho-
logical characteristics assessing problems in the social
context of a patient’s lifestyle. In allergic rhinoconjunc-
tivitis, two types of HRQoL measures—generic and dis-
ease-specific—are used [2, 3].The SQ grass sublingual
immunotherapy (SLIT)-tablet, developed for treatment of
grass pollen-induced rhinoconjunctivitis was launched in
Germany in November 2006 after gaining marketing
authorisation in several European countries. The SQ grass
SLIT-tablet has been developed according to one of the
largest clinical development programmes for a product of
allergy immunotherapy (AIT). More than 5600 patients
have been involved in randomised controlled clinical trials
(RCTs) performed in Europe and USA, which collectively
have demonstrated clinical efficacy and a favourable safety
profile in adults, adolescents and children [4–17]. Disease-
specific HRQoL using the Rhinoconjunctivitis Quality of
Life Questionnaire (RQLQ) [3] was also measured in the
large placebo-controlled RCTs with the SQ grass SLIT-
tablet. The trials have shown significant improvements in
the HRQoL in patients treated with the SQ grass SLIT-
tablet as compared to placebo [12, 14, 18].
As the patients’ perspective on improvements of dis-
ease-specific and everyday HRQoL is an important
parameter to assess the benefits of a therapeutic interven-
tion, the objective of our study was to explore the general
and disease-specific HRQoL during routine treatment with
the SQ grass SLIT-tablet in the real-life setting. The
HRQoL for the SQ grass SLIT-tablet was compared to the




The study was designed as a multicentre, open, uncon-
trolled and observational study according to non-interven-
tional post-marketing surveillance studies mentioned in the
German drug law analysed by epidemiological methods
after marketing authorisation. Study period was between
November 2006 and March 2009. Patients who contacted
their doctor because of allergic rhinoconjunctivitis during
the grass pollen season (GPS) before starting AIT in 2007
(GPS1) and who were potentially eligible for treatment
with the SQ grass SLIT-tablet (GRAZAX Phleum pra-
tense 75,000 SQ-T/2,800 BAU, ALK, Hørsholm, Den-
mark) were asked to assess their HRQoL in GPS1
(HRQoL1) and to return after GPS1 either to start AIT and
take symptomatic medication as needed or stay only with
symptomatic medication (nasal, topical medication, eye
drops/oral antihistamines/oral corticosteroids/b-agonists/
bronchially applied corticosteroids/other to be specified)
without AIT for assessment of their HRQOL outside the
grass pollen season (HRQoL2). All patients were asked to
return within or shortly after the following GPS (GPS2) for
assessment of their HRQoL (HRQoL3). The SQ grass
SLIT-tablet group in this study consisted of all patients
who returned after GPS1 and started treatment with the
SQ grass SLIT-tablet (a maximum of four patients per
site). The control group in a first step consisted of ‘all other
patients’ included in the study. For comparison of the
HRQoL data between the SQ grass SLIT-tablet group and
the symptomatic medication control group without AIT the
patients who: 1) returned after GPS1 to start treatment with
the SQ grass SLIT-tablet but did not participate in the
study, 2) returned after GPS1 to start another AIT and 3)
did not return after the screening visit, were excluded from
the control group. Furthermore, patients with HRQoL data
that were not suitable for a comparison of HRQoL3 versus
HRQoL1 were excluded. Patients who had their first visit
after GPS1 were evaluated with respect to changes in
HRQoL scores HRQoL3 (in GPS2) versus HRQoL2 (after
GPS1) while patients who had only an off-season visit after
GPS2 were not evaluated with respect to HRQoL.
Treatment with the SQ grass SLIT-tablet was started
after GPS1 and continued for about 12 months until the end
of GPS2 (Fig. 1).
Sites were distributed all over Germany to minimize a
potential investigator bias. Physicians were asked to
include patients in a consecutive order dependent on the
patient’s willingness to participate in the study to reduce a
potential selection bias.
2.2 Ethics and Data Protection
According to German drug law, non-interventional post-
marketing studies are notified to the authorities. If only
data on treatment as part of the routine medical practice are
recorded, these studies are not subject to approval by an
independent ethics committee. Patients were asked for their
consent to participate in the study. For recording and
evaluation of data patients were assigned a three-digit
patient number. Direct identification of the patients was
restricted to the physician’s offices participating in the
study.
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2.3 Patients
To be included in the study with the SQ grass SLIT-
tablet, patients had to give their consent and be candi-
dates for AIT with the SQ grass SLIT-tablet according
to normal clinical practice and the indications and con-
traindications described in the summary of product
characteristics (SmPC) [19]. Indications for treatment
according to the SmPC are: grass pollen-induced rhinitis
and conjunctivitis in adult patients with clinically rele-
vant symptoms and diagnosed with a positive skin-prick
test and/or specific immunoglobulin E (IgE) test to grass
pollen. Contraindications are: hypersensitivity to any of
the excipients (fish-gelatine, mannitol, sodium hydrox-
ide), malignancy or systemic diseases affecting the
immune system, e.g. autoimmune diseases, immune
complex diseases or immune deficiency diseases,
inflammatory conditions in the oral cavity with severe
symptoms such as oral lichen planus with ulcerations or
severe oral mycosis and patients with uncontrolled or
severe asthma [in adults: forced expiratory volume in 1 s
(FEV1) \70 % of predicted value after adequate phar-
macologic treatment].
2.4 Assessments
HRQoL was self-reported by all patients by means of the
12-Item Short Form Health Survey (SF-12, consisting of 12
items in 8 domains which can be summarised to the two
major physical and mental component scores) [2], to assess
general HRQoL (score range 0 to 100, 100 = optimal
HRQoL) and to assess disease-specific HRQoL by the
Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ,
assessing the seven domains: activity limitation, sleep
problems, non-nose/eye-symptoms, practical problems,
nasal symptoms, eye symptoms, emotional function on a
scale 0–6 with 0 = ’not troubled’ and 6 = ’extremely
troubled’) [3]. At a screening visit (S) in GPS1 the baseline
HRQoL was assessed (HRQoL1) independently from the
intended further treatment of the patient by AIT after
GPS1. Furthermore, as baseline characteristics of the
patients the clinical manifestation of allergy (rhinitis/con-
junctivitis/bronchial asthma/atopic dermatitis/other), the
medication prescribed (nasal, topical medication, eye
drops/oral antihistamines/oral corticosteroids/b-agonists/
bronchially applied corticosteroids/other to be specified)
and the severity of the allergy were recorded by means of
Clinical Global Impression (CGI) on a seven-step scale
(not at all ill/borderline ill/mildly ill/moderately ill/-
markedly ill/severely ill/among the most extremely ill)
[20]. The study visits and HRQoL assessments are
explained in Fig. 1.
The severity of symptoms in GPS1 (at nose, eyes, lung
and skin) and prescription of further symptomatic medi-
cation was recorded retrospectively in all patients who
returned to the physician’s office after GPS1 when patients
were asked to assess their off-season HRQoL (HRQoL2).
In patients who had agreed to being treated with the SQ
grass SLIT-tablet, treatment was initiated by the first
administration in the physician’s office at visit 1 (V1).
These patients were followed at visits every 3 months (V2–
V5) when returning to the physician’s office for renewal of
prescriptions for the SQ grass SLIT-tablet. At V2–V5,
adherence, adverse events (AEs) and any discontinuations
(including reasons for discontinuation) were recorded by
the physician. Serious AEs were notified to the authorities,
if applicable according to legal pharmacovigilance
procedures.
At the final visit within (V4) or after GPS2 (V5)
depending on whether the patient visited the physician’s
office for renewal of prescriptions of the SQ grass SLIT-
tablet, symptoms and use of symptomatic medication
during GPS2 were recorded.
V5     12  HRQoL3
V1      0    HRQoL2  
S              HRQoL1  
V2      3
V3      6 





1st administration of     
SQ grass SLIT-tablet
S: screening of patients 
eligible for AIT 
Fig. 1 Study diagram. All patients eligible for AIT were asked to fill
in HRQoL instruments for general HRQoL (SF-12) and disease-
specific HRQoL (RQLQ) at the screening visit (S) within the grass
pollen season (GPS1) [HRQoL1], after GPS1 (HRQOL2) and in the
following grass pollen season (GPS2) [HRQoL3]. Patients who did
not start treatment with the SQ grass SLIT-tablet and were not
treated by another AIT were evaluated as symptomatic medication
control group. Patients who returned after GPS1 and were treated with
the SQ grass SLIT-tablet started the first administration of the SQ
grass SLIT-tablet at visit 1 (V1) and were followed up at visits every
3 months (V2-V5). AIT allergy immunotherapy, GPS grass pollen
season, HRQoL health-related quality of life, SLIT sublingual
immunotherapy, V visit
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2.5 Statistical Methods
For data analysis, descriptive statistical methods and
exploratory tests for the comparison of independent sub-
groups were used (t test, U test, v2 test). Patients with
evaluable HRQoL data in and/or after GPS1 and in GPS2
in the group treated with the SQ grass SLIT-tablet were
compared with patients in the symptomatic medication
group without AIT. The comparison covers changes of
HRQoL in-season (HRQoL3 vs. HRQoL1) and in-season
versus off-season (HRQoL3 vs. HRQoL2) [t test], and
improvement rates (v2 test). No imputation was performed
in case of missing data, but all available data were used to
their full extent. AEs were coded according to the current
version of the Medical Dictionary for Regulatory Activities
(MedDRA). AEs and adverse drug reactions (ADRs) were
displayed for patients and on the level of events including
multiple occurrences by patient. The principal statistical
software used was Statistical Analysis System (SAS),
versions 9.3.
3 Results
3.1 Disposition of Patients
Overall, data for 576 patients recorded from 155 allergists’
offices in Germany were analysed, 364 patients treated
with the SQ grass SLIT-tablet could be analysed for
safety and 211 grass pollen-allergic patients as controls
(Fig. 2). HRQoL data were available for 320 patients
treated with the SQ grass SLIT-tablet and 192 patients in
the control group. Symptomatic medication prescribed at
baseline (in GPS1) was in the SLIT-tablet group (multiple
ratings): nasal, topical medication, eye drops 226 (70.6 %)
patients, oral antihistamines 248 (77.5 %), oral corticos-
teroids 42 (13.1 %), b-agonists 12 (3.8 %), bronchially
applied corticosteroids 42 (13.1 %), others 10 (3.1 %) and
in the control group: nasal, topical medication, eye drops
124 (64.6 %) patients, oral antihistamines 248 (69.8 %),
oral corticosteroids 42 (10.9 %), b-agonists 12 (4.2 %),
bronchially applied corticosteroids 20 (10.4 %), others 1
(0.5 %). Patients who were treated with the SQ grass
SLIT-tablet, but did not participate in the study (N = 30),
patients treated by another AIT than the SQ grass SLIT-
tablet (N = 27) and patients who did not return (N = 30)
were excluded from the control group to obtain the
symptomatic medication control group used for compar-
ison of the HRQoL data between the SQ grass SLIT-
tablet group and the symptomatic control group without
AIT.
The baseline characteristics of all patients who provided
HRQoL data and were eligible for a comparison of GPS2
and GPS1 (HRQoL3 vs. HRQoL1), are shown in Table 1.
No larger differences between the SQ grass SLIT-tablet
group and the symptomatic medication control group were
All patients screened (N=576)
SQ® grass SLIT-tablet (n=364) Controls (n=211) 
No HRQoL data (n=44) No HRQoL data (n=19)
At least 1 HRQoL assessment (n=320) At least 1 HRQoL assessment (n=192) 
Not evaluable:  
HRQoL3 vs. HRQoL1 (N=134) 
SQ® grass SLIT-tablet (N=186) 
HRQoL3 vs. HRQoL1 (N=138) 
HRQoL3 vs. HRQoL2 (N=179) 
Symptomatic medication (N=64) 
HRQoL3 vs. HRQoL1 (N=48) 
HRQoL3 vs. HRQoL2 (N=59) 
Not evaluable: 
 SLIT-tablet outside study (N=30) 
 Other AIT (N=27) 
 Did not return (N=30) 
HRQoL3 vs. HRQoL1 (N=41) 
Missing data (n=1) 
Comparison of HRQoL 
Fig. 2 Flow diagram. AIT
allergy immunotherapy, HRQoL
health-related quality of life,
SLIT sublingual immunotherapy
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observed with respect to age and gender. The frequency of
bronchial asthma was higher in the SQ grass SLIT-tablet
group, but not statistically significant. However, patients in
the SQ grass SLIT-tablet group had a higher severity of
allergy according to CGI with more patients assessed as
‘markedly ill’ as compared with the symptomatic medi-
cation control group. Accordingly, SF-12 and RQLQ
scores of HRQoL1 (in GPS1) and HRQoL2 (after GPS1)
were significantly higher in the SQ grass SLIT-tablet
group than in the symptomatic medication control group.
For patients in the SQ grass SLIT-tablet group, a different
attitude towards AIT (more patients were interested in AIT
with the SQ grass SLIT-tablet and fewer patients were
sceptical or refused AIT with the SQ grass SLIT-tablet)
was recorded as compared to the symptomatic medication
control group at the screening visit (S) in GPS1.
For 134 patients treated with the SQ grass SLIT-tablet
and 41 allergic patients in the control group, no HRQoL
data were available for comparison of HRQoL in GPS1 and
GPS2 (HRQoL3 vs. HRQoL1). HRQoL data were available
for analysis in GPS2 versus GPS1 for 138 patients in the
SQ grass SLIT-tablet group and 48 patients in the
symptomatic medication control group, and HRQoL data
for analysis in GPS2 versus outside GPS1 (HRQoL3 vs.
HRQoL2) for 179 patients in the SQ grass SLIT-tablet
group and 59 patients in the symptomatic medication
control group (Table 2).
3.2 General HRQoL (SF-12)
The overall baseline results from SF-12 overall score and
the results for the physical and mental component scores in
GPS1 (HRQoL1) were lower in the SQ grass SLIT-tablet
group than in the symptomatic medication control group
(Table 2) corresponding to the higher baseline severity of
the allergic disease assessed according to the CGI-scale in
the SQ grass SLIT-tablet group (Table 1).
In the SQ grass SLIT-tablet group, the overall SF-12
results as well as the physical and mental component scores
markedly increased in the first GPS with treatment by the
SQ grass SLIT-tablet (GPS2) compared with GPS1 at
baseline (HRQoL3 vs. HRQoL1) with largest improvement
for the physical component score. In the symptomatic
medication control group, SF-12 scores slightly decreased.
The differences between the mean score changes were
statistically significant (p\ 0.0001, t test). Changes in SF-
12 scores between HRQoL3 (GPS2) and HRQoL1 at
baseline (GPS1) after 9 to 12 months of treatment are
presented in Fig. 3. Mean overall SF-12 scores and phys-
ical and mental component scores decreased only slightly
in GPS2 (HRQoL3) as compared with scores outside GPS2
(HRQoL2) in the SQ grass SLIT-tablet group
(mean ± SD)—overall: (-1.6 ± 15.3); physical: (-
2.3 ± 18.7); mental: (-1.2 ± 15.9), but decreased mark-
edly in the symptomatic medication control group—
Table 1 Baseline characteristics of patients with evaluable health-related quality of life (HRQoL) data
Characteristic SQ grass SLIT-tablet group Symptomatic medication control group
Number of patients 186 64
Median age (range), years 32.0 (12–68) 35.5 (16–63)
Patients\18 years, N (%) 9 (4.8) 2 (3.1)
Sex, N (%)
Men 91 (48.9) 29 (45.3)
Women 95 (51.1) 35 (54.7)
Bronchial asthma, N (%) 54 (29.0) 12 (18.8)
Severity of allergy: Clinical Global Impression (CGI), mean (SD) 4.70 (0.67) 4.11 (0.68)
CGI, N (%)
Not at all ill – –
Borderline ill 1 (0.5) 1 (1.6)
Mildly ill 4 (2.2) 7 (11.3)
Moderately ill 58 (31.4) 39 (62.9)
Markedly ill 109 (58.9) 14 (22.6)
Severely ill 12 (6.5) 1 (1.6)
Extremely ill 1 (0.5) –
Attitude towards immunotherapy with SQ grass SLIT-tablet, N (%)
Interested in immunotherapy with the SQ grass SLIT-tablet 181 (97.3) 16 (25.0)
Sceptical about immunotherapy with the SQ grass SLIT-tablet 5 (2.7) 26 (40.6)
Refused immunotherapy with the SQ grass SLIT-tablet – 22 (34.4)
SLIT sublingual immunotherapy
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overall: (-10.4 ± 14.1); physical: (-12.3 ± 18.5); men-
tal: (-8.2 ± 13.9). The differences between the mean
score changes of the two groups were statistically signifi-
cant (p\ 0.01, t test).
In the SQ grass SLIT-tablet group, 98 of 138 patients
(71.0 %) showed improvements of their general intra-sea-
sonal HRQoL according to the overall SF-12 score whereas
17 of 48 (35.4 %) patients had an improvement in the
symptomatic medication control group (p\ 0.0001,
v2 test).
3.3 Disease-Specific HRQoL (RQLQ)
The baseline RQLQ scores (overall score as well as scores
of the seven individual domains) in GPS1 (HRQoL1) were
higher in the SQ grass SLIT-tablet group compared with
the group of patients receiving symptomatic treatment
without AIT (Table 2). This was in line with the pattern
observed for the SF-12 scores. A marked improvement in
the overall RQLQ score (-1.31 ± 0.96) between the
baseline scores in GPS1 (HRQoL1) and the scores in GPS2
(HRQoL3) was observed for the group of patients treated
with the SQ grass SLIT-tablet. Largest improvements
from baseline in the SQ grass SLIT-tablet group were
observed in the domains: nose symptoms (-1.75 ± 1.44),
practical problems (-1.72 ± 1.53) and eye symptoms (-
1.39 ± 1.37). In the symptomatic medication control group
a slight increase of the overall score (?0.10 ± 0.74) was
observed corresponding to a slight deterioration of disease-
specific HRQoL (Fig. 4). The differences in the mean score
changes between the two groups were statistically signifi-
cant (p\ 0.0001, t test). In the SQ grass SLIT-tablet
group, 121 of 138 (87.7 %) patients showed improvements
in their disease-specific intra-seasonal HRQoL versus 19 of
48 (39.6 %) patients in the symptomatic medication control
group (p\ 0.0001, v2 test).
When comparing the RQLQ scores in GPS2 (HRQoL3)
with the scores observed outside GPS1 (HRQoL2) in
patients treated with the SQ grass SLIT-tablet, scores
slightly increased (0.22 ± 1.29 for the overall score) but
markedly increased in the symptomatic medication control
group (1.24 ± 1.30).
Table 2 Mean health-related quality of life (HRQoL) scores (±SD) in patients with assessments at HRQoL1 (in GPS1), HRQoL2 (after GPS1)
and HRQoL3 (in GPS2)
Mean HRQoL scores (±SD) in patients with assessments
HRQoL3 and HRQoL1
Mean HRQoL scores (±SD) in patients with
assessments HRQoL2 and HRQoL3
SQ grass SLIT-tablet group
(N = 138)
Symptomatic medication
control group (N = 48)
SQ grass SLIT-tablet
group (N = 179)
Symptomatic medication

















SF-12 (score range 0–100)a
Overall score 64.8 (17.7) 76.1 (13.9) 71.4 (16.6) 68.0 (19.5) 77.2 (14.0)c 75.6 (15.2) 82.2 (11.5)d 72.3 (16.9)
Physical component
score
65.5 (21.6) 78.5 (15.8) 72.3 (19.9) 69.5 (20.3) 80.5 (16.3) 78.2 (16.7) 85.4 (12.4) 73.1 (18.5)
Mental component
score
64.3 (17.7) 74.6 (15.3) 70.8 (17.5) 67.0 (20.6) 75.0 (15.3) 73.8 (16.3) 80.1 (13.1) 71.9 (17.9)
RQLQ (score range 0–6)b
Overall score 2.62 (0.90) 1.31 (0.96) 2.18 (0.93) 2.28 (1.03) 1.13 (1.10) 1.36 (1.05) 0.74 (0.85) 1.98 (1.08)
Activity limitation 2.74 (1.09) 1.47 (1.15) 2.28 (1.19) 2.48 (1.34) 1.17 (1.27) 1.49 (1.23) 0.85 (1.18) 2.22 (1.39)
Sleep problems 2.26 (1.27) 1.19 (1.01) 1.95 (1.44) 2.08 (1.30) 1.04 (1.13) 1.22 (1.13) 0.69 (0.83) 1.75 (1.33)
Non-nose/eye
symptoms
2.21 (1.14) 1.14 (1.01) 1.92 (1.07) 2.04 (1.13) 1.07 (1.09) 1.20 (1.08) 0.70 (0.86) 1.73 (1.09)
Practical problems 3.41 (1.30) 1.68 (1.44) 3.02 (1.33) 2.88 (1.42) 1.41 (1.51) 1.77 (1.51) 0.94 (1.29) 2.57 (1.46)
Nasal symptoms 3.46 (1.21) 1.70 (1.30) 2.74 (1.16) 2.90 (1.31) 1.42 (1.47) 1.76 (1.34) 0.94 (1.15) 2.63 (1.37)
Eye symptoms 2.53 (1.28) 1.14 (1.08) 2.06 (1.25) 2.12 (1.10) 0.91 (1.23) 1.22 (1.17) 0.53 (0.85) 1.87 (1.13)
Emotional function 2.20 (1.10) 1.05 (1.04) 1.68 (1.11) 1.81 (1.14) 1.02 (1.15) 1.08 (1.09) 0.64 (0.88) 1.48 (1.12)
GPS grass pollen season, RQLQ Rhinoconjunctivitis Quality of Life Questionnaire, SF-12 12-Item Short Form Health Survey, SLIT sublingual
immunotherapy
a SF-12: optimal HRQoL (100)
b RQLQ: optimal HRQoL (0)
c N = 178
d N = 58
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3.4 Assessment of Treatment Effect with the SQ
Grass SLIT-Tablet
Median duration of treatment with the SQ grass SLIT-
tablet was 11.5 (mean 10.89 ± 3.44 SD) months. The
proportion of patients treated with the SQ grass SLIT-
tablet with improved symptoms or patients who became
free of symptoms in GPS2 versus GPS1 (baseline) was
78.5 % for nose symptoms (12.1 % became free of nose
symptoms), 73.6 % for eye symptoms (28.1 % became free
of eye symptoms), 75.5 % for bronchial symptoms (49.7 %
became free of bronchial symptoms) and 52.1 % for skin
symptoms (40.8 % became free of skin symptoms). The
proportion of patients who used additional symptomatic
medication in the SQ grass SLIT-tablet group decreased
from 96.5 % in GPS1 (baseline) to 52.1 % in GPS2.
3.5 Adherence and Tolerability
Between 77.2 % out of 189 patients with data for the fourth
prescription interval and 80.1 % of patients out of 331
patients (two missing values) with data for the first asses-
sed prescription interval were assessed to have taken the
SQ grass SLIT-tablet regularly (one tablet per day) during
the study. The question ‘did the patient take the SQ grass
SLIT-tablet regularly in all documented prescription
intervals’ was answered ‘yes’ in 63.2 % out of 331 patients
(two missing values) with initiation of treatment with the
SQ grass SLIT-tablet who had been included in the study
and had at least one follow-up visit. Treatment with the
SQ grass SLIT-tablet was continued after the last visit of
the study in 230 out of 364 (63.2 %) patients who initially
started treatment.
AEs were reported in 17.9 % of patients treated with the
SQ grass SLIT-tablet. The majority of these events were
judged to be related to the administration of the SQ grass
SLIT-tablet and occurred at the first administration. None
of the AEs were serious. Treatment with the SQ grass
SLIT-tablet was discontinued due to AEs in 18 patients—
in the majority of the patients due to local reactions at the
application site in the mouth, and cough, respiratory dis-
tress, exanthema and urticaria (each in a single case); 10
patients were medically treated, primarily by antihistami-
nes (allergic rhinitis/conjunctivitis, local reactions at the
application site, exanthema/itch, anxiety state) and by an
aerosol due to cough and by a beta-blocker due to hyper-
tension. The most frequently reported AEs were local
reactions at the administration site in the mouth (oral
pruritus, paraesthesia oral, oedema mouth and swollen
lip/tongue).
4 Discussion
HRQoL self-assessed by patients is very important as an
outcome parameter for measurement of patients’ individ-
ually perceived benefit and for analysis of cost-effective-
ness of a therapeutic intervention [1]. Both disease-specific
and general HRQoL instruments have been validated in
different languages and published [2, 3]. Improvements of
the disease-specific HRQoL are especially important for
long-term treatments like AIT.
Our study has shown that patients routinely treated in
the allergist’s office with the SQ grass SLIT-tablet per-
ceive remarkable improvements in general and disease-
specific HRQoL after approximately 12 months of treat-
ment as compared to baseline.











HRQoL3 vs. HRQoL2 HRQoL3 vs. HRQoL1
HRQoL-decrease HRQoL-increase 
Fig. 3 Changes in SF-12-scores for the SF-12 overall score and the
physical and mental component scores in the SQ grass SLIT-tablet
group (a) and the symptomatic medication control group (b) between
HRQoL-assessments in grass pollen season 2 (GPS2) after 9 to 12
months of treatment and in baseline grass pollen season 1 (GPS1),
(HRQoL3 vs. HRQoL1), and between HRQoL-assessments in grass
pollen season 2 (GPS2) and after GPS1 (outside the grass pollen
season), (HRQoL3 vs. HRQoL2). Differences in changes between the
SQ grass SLIT-tablet group and the symptomatic medication control
group were statistically significant (overall score: p = 0.0003, mental
component score: p = 0.0028, physical component score:
p = 0.0005). HRQoL health-related quality of life, SF-12 12-Item
Short Form Health Survey, SLIT sublingual immunotherapy
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All improvements in the intra-seasonal disease-specific
HRQoL for the SQ grass SLIT-tablet group were clearly
above the threshold of 0.5 for a clinically important
improvement previously defined by Juniper [21, 22].
No improvement in the HRQoL was observed in
patients treated only with unspecific commonly used
symptomatic medication such as antihistamines, corticos-
teroid nasal sprays and/or eye drops. The HRQoL for the
allergic patients treated with symptomatic medication did
not change, but tended to deteriorate as was to be expected
for patients with unspecific treatment of allergy. The dif-
ferences in HRQoL scores between AIT with the SQ
grass SLIT-tablet and the unspecific treatment by symp-
tomatic medication were highly significant. It has to be
taken into consideration that the allocation of the patients
to the SQ grass SLIT-tablet group or to the symptomatic
medication control group was performed according to real-
life procedures (i.e. as an agreement between physician and
patient) and not by randomisation as in a RCT. Accord-
ingly, the SQ grass SLIT-tablet group and symptomatic
medication control group were only comparable with
respect to age and gender, but different for frequency of
asthma and with respect to a higher severity of allergy
according to the CGI scale and a different attitude towards
AIT with the SQ grass SLIT-tablet and impairment of
HRQoL at baseline.
Nevertheless, in our study improvements in HRQoL
were observed that confirm the results from previously
conducted RCTs with the SQ grass SLIT-tablet [12, 14,
18] and indicate the potential for significant improvements
in HRQoL after treatment with the SQ grass SLIT-tablet
in real-life.
Limitations of our study are those of a prospective,
open-label, uncontrolled observational study in the real-life
setting. In order to minimise a potential investigator bias,
sites distributed all over Germany were involved. For
reduction of a potential selection bias physicians were
asked to include patients in a consecutive order according
to the consent of the patients to be included in the study. A
source of potential bias in comparisons of the HRQoL
scores between GPS2 and GPS1 is the number of pollen
grains the individual patient has been exposed to and the
natural variability of the grass-pollen load in Germany in
the two GPS compared in our study potentially inducing an

























Fig. 4 Changes in RQLQ
scores for individual domains
and overall scores in the SQ
grass SLIT-tablet group (a) and
the symptomatic medication
control group (b) between
HRQoL assessments in grass
pollen season 2 (GPS2) after 9
to 12 months of treatment and in




and after GPS1 (outside the
grass pollen season), (HRQoL3
vs. HRQoL2). Differences in
changes between the two groups
were statistically significant for
the overall scores and the scores
for all seven RQLQ-domains
(p\ 0.0001). HRQoL health-
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increase in perceived HRQoL by patients in case of a lower
pollen exposure in GPS2 after about one year of treatment
compared with baseline GPS1.
5 Conclusion
In conclusion, routine treatment with the SQ grass SLIT-
tablet resulted in clear improvements in disease-specific
and general HRQoL as compared to unspecific treatment
with symptomatic medication only.
Acknowledgments We would like to thank all physicians who
participated in the study.
Compliance with Ethical Standards
Funding ALK sponsored this study and was involved in trial
design, data collection, analysis and interpretation.
Conflicts of interest A. Horn and H. Zeuner received remuneration
from ALK for the documentation of patient data from their practice.
They previously participated as investigators in clinical trials spon-
sored by ALK. A Horn received remuneration from ALK for edu-
cational presentations and is advisory board member for ALK.
J Schnitker was funded by ALK as Clinical Research Organisation
(CRO) in the study. H Wolf and E Wu¨stenberg are employees of
ALK. The investigators received remuneration from ALK for the
documentation of treatment of their patients. IAS GmbH received as
CRO remuneration from ALK for its services in biometrical planning,
data management and statistical analysis of the study.
Ethical approval All procedures in this study were in accordance
with the 1964 Helsinki declaration (and its amendments), since only
data on treatment as part of the routine medical practice were
recorded the study was not subject to approval by an independent
ethics committee.
Informed consent Patients were asked for their consent to partici-
pate in the study. Written informed consent was not required because
only data as part of the routine medical practice were recorded.
Open Access This article is distributed under the terms of the
Creative Commons Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/by-nc/4.0/), which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided you give appropriate credit to the original
author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made.
References
1. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ,
Togias A, et al. Allergic Rhinitis and its Impact on Asthma
(ARIA) 2008 update (in collaboration with the World Health
Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl
86):8–160.
2. Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health
Survey: construction of scales and preliminary tests of reliability
and validity. Med Care. 1996;34(3):220–33.
3. Juniper EF, Guyatt GH. Development and testing of a new
measure of health status for clinical trials in rhinoconjunctivitis.
Clin Exp Allergy. 1991;21(1):77–83.
4. Malling H-J, Lund L, Ipsen H, Poulsen LK. Safety and
immunological changes during specific sublingual immunother-
apy with SQ standardized grass allergen tablets. J Investig
Allergol Clin Immunol. 2006;16:162–8.
5. Kleine-Tebbe J, Ribel M, Herold DA. Safety of a SQ-standard-
ised grass allergen tablet for sublingual immunotherapy: a ran-
domized, placebo-controlled trial. Allergy. 2006;61:181–4.
6. Calderon M, Essendrop M. Specific immunotherapy with high
dose SQ standardised grass allergen tablets was safe and well
tolerated. J Investig Allergol Clin Immunol. 2006;16:338–44.
7. Iban˜ez MD, Kaiser F, Knecht R, Armentia A, Scho¨pfer H,
Tholstrup B, Bufe A. Safety of specific sublingual immunother-
apy with SQ standardized grass allergen tablets in children.
Pediatr Allergy Immunol. 2007;18:516–22.
8. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S.
Sublingual immunotherapy with once-daily grass allergen tablets:
a randomized controlled trial in seasonal allergic rhinoconjunc-
tivitis. J Allergy Clin Immunol. 2006;117:802–9.
9. Dahl R, Kapp A, Colombo G, de Monchy J, Rak S, Emminger W,
Ferna´ndez Rivas M, Ribel M, Durham SR. Efficacy and safety of
sublingual immunotherapy with grass allergen tablet for seasonal
allergic rhinoconjunctivitis. J Allergy Clin Immunol.
2006;118:434–40.
10. Dahl R, Stender A, Rak S. Specific immunotherapy with SQ
standardized grass allergen tablets in asthmatics with rhinocon-
junctivitis. Allergy. 2006;61:185–90.
11. Bufe A, Eberle P, Franke-Beckmann E, Funck J, Kimmig M,
Klimek L, Knecht R, Stephan V, Tholstrup B, Weibhaar C,
Kaiser F. Safety and efficacy in children of an SQ-standardized
grass allergen tablet for sublingual immunotherapy. J Allergy
Clin Immunol. 2009;23:167–73.
12. Dahl R, Kapp A, Colombo G, De Monchy JG, Rak S, Emminger
W, Riis B, Grønager PM, Durham SR. Sublingual grass allergen
tablet immunotherapy provides sustained clinical benefit with
progressive immunologic changes over 2 years. J Allergy Clin
Immunol. 2008;121:512–8.
13. Durham SR, Emminger W, Kapp A, Colombo G, de Monchy
JGR, Rak S, Scadding GK, Andersen JS, Riis B, Dahl R. Long-
term clinical efficacy in grass pollen-induced rhinoconjunctivitis
after treatment with SQ-standardized grass allergy immunother-
apy tablet. J Allergy Clin Immunol. 2010;125:131–8.
14. Durham SR, Emminger W, Kapp A, de Monchy JGR, Rak S,
Scadding GK, Wurtzen PA, Andersen JS, Tholstrup B, Riis B,
Dahl R. SQ-standardized sublingual grass immunotherapy:
Confirmation of disease modification 2 years after 3 years of
treatment in a randomized trial. J Allergy Clin Immunol.
2012;129:717–25.
15. Blaiss M, Maloney J, Nolte H, Gawchik S, Yao R, Skoner DP.
Safety of timothy grass allergy immunotherapy tablets in north
American children and adolescents. J Allergy Clin Immunol.
2011;127:64–7.
16. Nelson HS, Nolte H, Creticos P, Maloney J, Wu J, Bernstein DI.
Efficacy and safety of timothy grass allergy immunotherapy
tablet in north american adults. J Allergy Clin Immunol.
2011;127:72–80.
17. Maloney J, Bernstein DI, Nelson H, Creticos P, He´bert J, Noonan
M, Skoner D, Zhou Y, Kaur A, Nolte H. Efficacy and safety of
grass sublingual immunotherapy tablet, MK-7243: a large ran-
domized controlled trial. Ann Allergy Asthma Immunol.
2014;112:146–53.
18. Frølund L, Durham SR, Calderon M, Emminger W, Andersen JS,
Rask P, Dahl R. Sustained effect of SQ-standardized grass allergy
Quality of Life with the SQ Grass SLIT-Tablet 461
immunotherapy tablet on rhinoconjunctivitis quality of life.
Allergy. 2010;65:753–7.
19. GRAZAX (75,000 SQ-T oral lyophilisate) [summary of product
characteristics] (2006). Wedel, Germany: ALK; dated Oct 2006.
20. Guy W. Clinical Global Impression. ECDEU assessment manual
for psychopharmacology, revised. Rockville: National Institute of
Mental Health; 1976.
21. Juniper EF. Quality of life questionnaires: does statistically sig-
nificant = clinically important? J Allergy Clin Immunol.
1998;102(1):16–7.
22. Juniper EF, Guyatt GH, Griffith LE, Ferrie PJ. Interpretation of
rhinoconjunctivitis quality of life questionnaire data. J Allergy
Clin Immunol. 1996;98(4):843–5.
23. Horn A, Zeuner H, Wolf H, Schnitker J, Wu¨stenberg E. Quality
of life during routine treatment with the SQ-standardised grass
allergy immunotherapy tablet. Allergy. 2010;65 (Suppl
92):579–80 (Poster presentation at the 29th EAACI-Congress,
05 to 09 June 2010, London, UK).
24. Wolf H, Horn A, Zeuner H, Schnitker J, Wu¨stenberg E. Leben-
squalita¨t wa¨hrend der Routine-Behandlung mit der SQ-standar-
disierten Gra¨ser-Allergie-Immuntherapietablette. Allergo J.
2010;19:S49 (Poster presentation at the 5th German Allergy
Congress, 08 to 11 September 2010 Hannover, Germany).
462 A. Horn et al.
